<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040664</url>
  </required_header>
  <id_info>
    <org_study_id>APV 20003</org_study_id>
    <nct_id>NCT00040664</nct_id>
  </id_info>
  <brief_title>A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years</brief_title>
  <official_title>A 48 Week, Phase II, Open-Label Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and GW433908/Ritonavir BID When Administered to HIV-1 Infected, Antiretroviral Naive and Experienced, Pediatric Subjects 2-18 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <brief_summary>
    <textblock>
      This is a 48-week study to collect additional information on the safety, tolerability,
      pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy)
      including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 48 Week, Phase II, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety,
      Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and
      GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Naive and
      Experience Pediatric Subjects 2 to 18 Years Old

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Treatment Due to Adverse Events</measure>
    <time_frame>Baseline through end of study (at least Week 168)</time_frame>
    <description>The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Drug-related Grade 2 to 4 Adverse Event</measure>
    <time_frame>Baseline through end of study (at least Week 168)</time_frame>
    <description>The number of participants with drug-related adverse events coded as Grade 2 (mild), Grade 3 (severe), or Grade 4 (life-threatening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or 4 Treatment-emergent Laboratory Abnormalities</measure>
    <time_frame>Baseline through end of study (at least Week 168)</time_frame>
    <description>The number of participants with Grade 3 (severe) or Grade 4 (life-threatening) laboratory abnormalities while on study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Steady State Plasma Amprenavir (APV) Parameter: AUC(0-tau)</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
    <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. AUC(0-tau)=area under the concentration curve from time 0 to tau.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Steady State Plasma APV Parameter: Cmax</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
    <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. Cmax= concentration maximum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Steady State Plasma APV Tmax</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
    <description>tmax: time after administration of the drug when maximum concentration is reached</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Steady State Plasma APV Parameter: CL/F</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
    <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. CL/F=apparent plasma clearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Steady State Plasma APV Parameter: t1/2</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
    <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. t1/2=elimination half-life. t1/2=elimination half-life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Least Squares Mean of Plasma APV Parameter: AUC0-tau</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
    <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Least Squares Mean of Plasma APV Parameter: Cmax</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4.</time_frame>
    <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Least Squares Mean of Plasma APV Parameter: Ctau</measure>
    <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4.</time_frame>
    <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt;400 Copies Per mL at Weeks 12, 48, 96, and 168 (Time to Loss of Virologic Response [TLOVR] Analysis)</measure>
    <time_frame>Weeks 12, 48, 96, and 168</time_frame>
    <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies per milliliter (mL) at Weeks 12, 48, 96, and 196. The percentage of participants with HIV-1 RNA &lt;400 copies/mL at Weeks 12, 48, 96, 168 was determined by the TLOVR algorithm with stratification by the six randomization strata. TLOVR analysis categorizes participants by treatment response. Responders were participants with confirmed viral load &lt;400copies/mL on two consecutive visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline HIV-1 RNA Values at Weeks 12, 48, 96, and 168 Visits</measure>
    <time_frame>Baseline and Weeks 12, 48, 96, and 168</time_frame>
    <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 12, 24, 48, 96, and 168. Change from Baseline was defined as the HIV-1 RNA level at Weeks 12, 24, 48, 96, and 168 minus the HIV-1 RNA level at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in CD4+ Values at Week 12, 48, 96, and 168 Visits</measure>
    <time_frame>Baseline and Weeks 12, 48, 96, and 168</time_frame>
    <description>A blood sample was drawn to determine the CD4+ cell count at Weeks 24, 48, 96, and 168. Change from Baseline was defined as the CD4+ cell count at Weeks 24, 48, 96, and 168 minus the CD4+ cell count at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With APV Resistance Associated HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline</measure>
    <time_frame>Time of virologic failure</time_frame>
    <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class. Virologic failure is defined as HIV-1 RNA greater than or equal to 400 copies/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>2 to 5 years (FPV/RTV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 to 11 years (FPV/RTV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 to 18 years (FPV/RTV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>ritonavir oral capsules or oral solution</description>
    <arm_group_label>12 to 18 years (FPV/RTV)</arm_group_label>
    <arm_group_label>2 to 5 years (FPV/RTV)</arm_group_label>
    <arm_group_label>6 to 11 years (FPV/RTV)</arm_group_label>
    <other_name>fosamprenavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosamprenavir</intervention_name>
    <description>fosamprenavir oral suspension or tablet</description>
    <arm_group_label>12 to 18 years (FPV/RTV)</arm_group_label>
    <arm_group_label>2 to 5 years (FPV/RTV)</arm_group_label>
    <arm_group_label>6 to 11 years (FPV/RTV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

          -  Male or females 2 to 18 years of age

          -  A female is eligible to enter and participate in this study if she is of:

          -  a. non-childbearing potential (i.e., physiologically incapable of becoming pregnant,
             including any female who is pre-menarchial); or,

          -  b. child-bearing potential with a negative serum pregnancy test at screen, a negative
             urine pregnancy test on Day 1 and who agrees to use one of the following methods of
             contraception (any contraception method must be used consistently and correctly, i.e.,
             in accordance with both the product label and the instructions of a physician). Note:
             hormonal contraceptives are not considered a sufficient form of contraceptive for this
             study.

          -  Complete abstinence from intercourse from 2 weeks prior to administration of study
             drugs, throughout the study and for 2 weeks after discontinuation of all study
             medications. Should a female subject of childbearing potential decide to become
             sexually active during the course of the study, she must be counselled and be willing
             to use one of the methods listed below:

          -  Double barrier contraception (male condom/spermicide, male condom/diaphragm,
             diaphragm/spermicide)

          -  Any intrauterine device (IUD) with published data showing that the expected failure
             rate is less than 1% per year (not all IUDs meet this criterion)

          -  Any other method with published data showing that the lowest expected failure rate for
             that method is less than 1% per year. All subjects participating in this study should
             be counselled on the practice of safe/safer sex.

          -  Parent or legal guardian (and subject whenever possible) has the ability to understand
             and provide written informed consent for the subject to participate in the trial.
             Verbal witnessed assent must be obtained from the subject whenever possible.

          -  Screening plasma HIV-1 RNA &gt; or =400copies/mL.

          -  Subject's who, in the investigator's opinion, and following resistance testing where
             appropriate, are able to construct an active NRTI backbone regimen consisting of 2
             NRTIs.

          -  Subjects must meet one of the following criteria:

          -  ART-na√Øve subjects are defined as having had &lt; 4 weeks (28 days) therapy with an NRTI,
             no previous therapy with an NNRTI and &lt; 1 week therapy with an HIV PI.

          -  ART-experienced subjects are defined as having had greater than 4 weeks (28 days)
             therapy with any NRTI(s) and any length of therapy with any NNRTI(s) and/or a PI.
             PI-experienced subjects will be eligible if they have previously been treated with &lt;
             three PIs, excluding AGENERASE. Prior therapy with a RTV boosted PI regimen will be
             considered as only 1 prior PI as long as the RTV dose was below that recommended for
             use of RTV as an antiretroviral agent. This specific criterion is not applicable to
             subjects in screening and/or enrolling after approval of Amendment No. 4. - For
             subjects screening and/or enrolling after the approval of Amendment No.4, PI naive
             subjects are defined as ART experienced subjects having less than one week of therapy
             with a PI and no prior experience with AGENERASE. Prior treatment with NNRTIs and
             NRTIs is permitted (however, subjects will NOT be permitted to receive concurrent
             NNRTI therapy while participating in this study)

          -  Exclusion Criteria:

          -  Prior history of having received amprenavir.

          -  Use of non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy within 14 days
             of study Day 1 or anticipated need for concurrent NNRTI therapy during the study
             period.

          -  Have had an AIDS defining illness (acute CDC Category C event) within 28 days of
             screening.

          -  Pregnant or lactating.

          -  Non-nucleoside reverse transcriptase inhibitor therapy within 14 days prior to study
             drug administration or anticipated need for concurrent NNRTI therapy during the study
             period.

          -  Subjects who, in the investigator's opinion, are not able to comply with the
             requirements of the study.

          -  An acute CDC Category C event (per 1993/1994 classification) and/or serious bacterial
             infection(s) within 28 days prior to study drug administration.

          -  Presence of a malabsorption syndrome or other gastrointestinal dysfunction which might
             interfere with drug absorption or render the subject unable to take oral medication.

          -  Presence of any serious medical condition (e.g., hemoglobinopathy, chronic
             anemia,diabetes, cardiac dysfunction and hepatitis) which, in the opinion of the
             investigator, might compromise the safety of the subject.

          -  Current grade 2 or higher serum lipase within 28 days prior to study drug
             administration and/or history of clinically relevant pancreatitis within the previous
             6 months. - Grade 3 or 4 transaminase levels (ALT and/or AST) within 28 days prior to
             study drug administration and/or clinically relevant hepatitis within the previous 6
             months.

          -  Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days
             of study drug administration or an anticipated need for such treatment within the
             study period.

          -  Treatment with immunomodulating agents (e.g., systemic corticosteroids, interleukins,
             interferons) or any agent with known anti-HIV activity (e.g., hydroxyurea or
             foscarnet) within 28 days of study drug administration.

          -  Treatment with any of the following medications within 28 days prior to receiving
             study medication or the anticipated need during the study:

          -  Amiodarone, astemizole, bepridil, bupropion, cisapride, clorazepate, clozapine,
             diazepin, dihydroergotamine, encainide, ergonovine, ergotamine, estazolam, flecainide,
             flurazepam, lovastatin, meperidine, methylergonovine, midazolam, pimozide, piroxicam,
             propafenone, propoxyphene, quinidine, rifabutin, simvastatin, terfenadine, triazolam,
             zolpidem (these drugs have been excluded for safety reasons).

          -  Carbamazepine, dexamethasone, phenobarbital, phenytoin, primidone, rifampin, St Johns
             Wort (these drugs have been excluded because they have the potential to decrease
             plasma protease inhibitor concentrations) - Systemic chemotherapeutic agents

          -  Treatment with other investigational drugs/therapies (note: treatments available
             through a Treatment IND or other expanded-access mechanism will be evaluated on a
             case-by-case basis in consultation with the sponsor) within 28 days prior to study
             drug administration

          -  History of drug or other allergy which, in the opinion of the investigator,
             contraindicates participation in the trial or known hypersensitivity to any study
             medications (e.g., documented hypersensitivity to a nucleoside analogue).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41150</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amadora</city>
        <zip>2700</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1150</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28047</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2002</study_first_submitted>
  <study_first_submitted_qc>July 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2002</study_first_posted>
  <results_first_submitted>August 6, 2009</results_first_submitted>
  <results_first_submitted_qc>February 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2010</results_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>HIV</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>ritonavir</keyword>
  <keyword>fosamprenavir</keyword>
  <keyword>LEXIVA</keyword>
  <keyword>AGENERASE</keyword>
  <keyword>amprenavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cohorts were recruited in parallel. All Age Cohorts were given the same treatment.</recruitment_details>
      <pre_assignment_details>The overall study population consisted of 69 participants presented as &quot;Overall Fosamprenavir (FPV)/ritonavir (RTV)&quot; in the Participant Flow section. Furthermore, the Overall FPV/RTV participants are stratified by age cohorts (Arms 2-4).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Fosamprenavir (FPV)/Ritonavir(RTV)</title>
          <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
        </group>
        <group group_id="P2">
          <title>2-5 Years FPV/RTV</title>
          <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD), 2-5 years</description>
        </group>
        <group group_id="P3">
          <title>6-11 Years FPV/RTV</title>
          <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD), 6-11 years</description>
        </group>
        <group group_id="P4">
          <title>12-18 Years FPV/RTV</title>
          <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD), 12-18 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69">All (69) enrolled on QD; 10 switched to twice daily. Participant flow not collected for this group.</participants>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient CD4 response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication adherence/compliance problems</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor taste</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pharmacokinetic target not achieved</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of formulation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-viability of oral suspension</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FPV/RTV</title>
          <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East and South East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Treatment Due to Adverse Events</title>
        <description>The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event.</description>
        <time_frame>Baseline through end of study (at least Week 168)</time_frame>
        <population>Safety Population: all participants with documented evidence of having received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV</title>
            <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Treatment Due to Adverse Events</title>
          <description>The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event.</description>
          <population>Safety Population: all participants with documented evidence of having received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertriglyceridaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkin's disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt;400 Copies Per mL at Weeks 12, 48, 96, and 168 (Time to Loss of Virologic Response [TLOVR] Analysis)</title>
        <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies per milliliter (mL) at Weeks 12, 48, 96, and 196. The percentage of participants with HIV-1 RNA &lt;400 copies/mL at Weeks 12, 48, 96, 168 was determined by the TLOVR algorithm with stratification by the six randomization strata. TLOVR analysis categorizes participants by treatment response. Responders were participants with confirmed viral load &lt;400copies/mL on two consecutive visits.</description>
        <time_frame>Weeks 12, 48, 96, and 168</time_frame>
        <population>The Intent-to-Treat Exposed (ITT [E]) Population consisted of all subjects with documented evidence of having received at least one dose of study drug. Results are stratified by previous protease inhibitor (PI) experience. Participants with previous PI experience may respond differently to FPV.</population>
        <group_list>
          <group group_id="O1">
            <title>PI-Naive</title>
            <description>Participants with equal to or less than 1 week of treatment with a Protease Inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>PI-Experienced</title>
            <description>Participants treated with equal to or less than 3 PIs (any length of time)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt;400 Copies Per mL at Weeks 12, 48, 96, and 168 (Time to Loss of Virologic Response [TLOVR] Analysis)</title>
          <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies per milliliter (mL) at Weeks 12, 48, 96, and 196. The percentage of participants with HIV-1 RNA &lt;400 copies/mL at Weeks 12, 48, 96, 168 was determined by the TLOVR algorithm with stratification by the six randomization strata. TLOVR analysis categorizes participants by treatment response. Responders were participants with confirmed viral load &lt;400copies/mL on two consecutive visits.</description>
          <population>The Intent-to-Treat Exposed (ITT [E]) Population consisted of all subjects with documented evidence of having received at least one dose of study drug. Results are stratified by previous protease inhibitor (PI) experience. Participants with previous PI experience may respond differently to FPV.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline HIV-1 RNA Values at Weeks 12, 48, 96, and 168 Visits</title>
        <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 12, 24, 48, 96, and 168. Change from Baseline was defined as the HIV-1 RNA level at Weeks 12, 24, 48, 96, and 168 minus the HIV-1 RNA level at Baseline.</description>
        <time_frame>Baseline and Weeks 12, 48, 96, and 168</time_frame>
        <population>ITT-E Population. Results are stratified by previous PI experience. Participants with previous PI experience may respond differently to FPV.</population>
        <group_list>
          <group group_id="O1">
            <title>PI-Naive</title>
            <description>Participants with equal to or less than 1 week of treatment with a Protease Inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>PI-Experienced</title>
            <description>Participants treated with equal to or less than 3 PIs (any length of time)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline HIV-1 RNA Values at Weeks 12, 48, 96, and 168 Visits</title>
          <description>A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 12, 24, 48, 96, and 168. Change from Baseline was defined as the HIV-1 RNA level at Weeks 12, 24, 48, 96, and 168 minus the HIV-1 RNA level at Baseline.</description>
          <population>ITT-E Population. Results are stratified by previous PI experience. Participants with previous PI experience may respond differently to FPV.</population>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" lower_limit="-3.12" upper_limit="-2.54"/>
                    <measurement group_id="O2" value="-2.03" lower_limit="-3.02" upper_limit="-0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" lower_limit="-3.31" upper_limit="-1.44"/>
                    <measurement group_id="O2" value="-1.65" lower_limit="-2.76" upper_limit="-1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" lower_limit="-3.14" upper_limit="-1.42"/>
                    <measurement group_id="O2" value="-1.76" lower_limit="-2.91" upper_limit="-0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" lower_limit="-3.49" upper_limit="-2.15"/>
                    <measurement group_id="O2" value="-2.39" lower_limit="-3.13" upper_limit="-0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in CD4+ Values at Week 12, 48, 96, and 168 Visits</title>
        <description>A blood sample was drawn to determine the CD4+ cell count at Weeks 24, 48, 96, and 168. Change from Baseline was defined as the CD4+ cell count at Weeks 24, 48, 96, and 168 minus the CD4+ cell count at Baseline.</description>
        <time_frame>Baseline and Weeks 12, 48, 96, and 168</time_frame>
        <population>ITT-E Population. Results are stratified by previous PI experience. Participants with previous PI experience may respond differently to FPV.</population>
        <group_list>
          <group group_id="O1">
            <title>PI-Naive</title>
            <description>Participants with equal to or less than 1 week of treatment with a PI</description>
          </group>
          <group group_id="O2">
            <title>PI-Experienced</title>
            <description>Participants treated with equal to or less than 3 PIs (any length of time)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in CD4+ Values at Week 12, 48, 96, and 168 Visits</title>
          <description>A blood sample was drawn to determine the CD4+ cell count at Weeks 24, 48, 96, and 168. Change from Baseline was defined as the CD4+ cell count at Weeks 24, 48, 96, and 168 minus the CD4+ cell count at Baseline.</description>
          <population>ITT-E Population. Results are stratified by previous PI experience. Participants with previous PI experience may respond differently to FPV.</population>
          <units>Cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="10" upper_limit="150"/>
                    <measurement group_id="O2" value="40" lower_limit="-30" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="75" upper_limit="280"/>
                    <measurement group_id="O2" value="120" lower_limit="0" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" lower_limit="55" upper_limit="280"/>
                    <measurement group_id="O2" value="40" lower_limit="-180" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="10" upper_limit="430"/>
                    <measurement group_id="O2" value="0" lower_limit="-220" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Drug-related Grade 2 to 4 Adverse Event</title>
        <description>The number of participants with drug-related adverse events coded as Grade 2 (mild), Grade 3 (severe), or Grade 4 (life-threatening).</description>
        <time_frame>Baseline through end of study (at least Week 168)</time_frame>
        <population>Safety Population: all participants with documented evidence of having received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>FPV Tablet</title>
            <description>Fosamprenavir 700 mg tablets/ritonavir 100 mg capsules once daily</description>
          </group>
          <group group_id="O2">
            <title>FPV Oral Suspension</title>
            <description>Fosamprenavir 50 mg/mL oral suspension/ritonavir 80 mg/mL oral solution once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Drug-related Grade 2 to 4 Adverse Event</title>
          <description>The number of participants with drug-related adverse events coded as Grade 2 (mild), Grade 3 (severe), or Grade 4 (life-threatening).</description>
          <population>Safety Population: all participants with documented evidence of having received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Grade 2-4 events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood triglycerides increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benign salivary gland neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood cholesterol increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoptysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertrichosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipodystrophy acquired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipohypertrophy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or 4 Treatment-emergent Laboratory Abnormalities</title>
        <description>The number of participants with Grade 3 (severe) or Grade 4 (life-threatening) laboratory abnormalities while on study treatment.</description>
        <time_frame>Baseline through end of study (at least Week 168)</time_frame>
        <population>Safety Population: all participants with documented evidence of having received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV</title>
            <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or 4 Treatment-emergent Laboratory Abnormalities</title>
          <description>The number of participants with Grade 3 (severe) or Grade 4 (life-threatening) laboratory abnormalities while on study treatment.</description>
          <population>Safety Population: all participants with documented evidence of having received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All parameters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Steady State Plasma Amprenavir (APV) Parameter: AUC(0-tau)</title>
        <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. AUC(0-tau)=area under the concentration curve from time 0 to tau.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The Pharmacokinetic (PK) Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Steady State Plasma Amprenavir (APV) Parameter: AUC(0-tau)</title>
          <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. AUC(0-tau)=area under the concentration curve from time 0 to tau.</description>
          <population>The Pharmacokinetic (PK) Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>hours*micrograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="34.2" upper_limit="65.4"/>
                    <measurement group_id="O2" value="47.6" lower_limit="27.0" upper_limit="84.0"/>
                    <measurement group_id="O3" value="75.5" lower_limit="23.4" upper_limit="244"/>
                    <measurement group_id="O4" value="71.8" lower_limit="10.6" upper_limit="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Steady State Plasma APV Parameter: Cmax</title>
        <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. Cmax= concentration maximum.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Steady State Plasma APV Parameter: Cmax</title>
          <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. Cmax= concentration maximum.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>micrograms/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" lower_limit="3.76" upper_limit="6.58"/>
                    <measurement group_id="O2" value="5.07" lower_limit="2.50" upper_limit="10.3"/>
                    <measurement group_id="O3" value="6.88" lower_limit="4.31" upper_limit="11.0"/>
                    <measurement group_id="O4" value="7.70" lower_limit="2.70" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With APV Resistance Associated HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline</title>
        <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class. Virologic failure is defined as HIV-1 RNA greater than or equal to 400 copies/mL.</description>
        <time_frame>Time of virologic failure</time_frame>
        <population>Participants in the ITT-E Population who met the virologic failure definition. Results are stratified by previous PI experience. Participants with previous PI experience may respond differently to FPV.</population>
        <group_list>
          <group group_id="O1">
            <title>PI-Naive</title>
            <description>Participants with equal to or less than 1 week of treatment with a PI</description>
          </group>
          <group group_id="O2">
            <title>PI-Experienced</title>
            <description>Participants treated with equal to or less than 3 PIs (any length of time)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With APV Resistance Associated HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline</title>
          <description>A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class. Virologic failure is defined as HIV-1 RNA greater than or equal to 400 copies/mL.</description>
          <population>Participants in the ITT-E Population who met the virologic failure definition. Results are stratified by previous PI experience. Participants with previous PI experience may respond differently to FPV.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Steady State Plasma APV Tmax</title>
        <description>tmax: time after administration of the drug when maximum concentration is reached</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Median Steady State Plasma APV Tmax</title>
          <description>tmax: time after administration of the drug when maximum concentration is reached</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.95" upper_limit="4.02"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.75" upper_limit="2.07"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.92" upper_limit="2.00"/>
                    <measurement group_id="O4" value="3.78" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Steady State Plasma APV Parameter: CL/F</title>
        <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. CL/F=apparent plasma clearance.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years vs. Historical Adult Data</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Steady State Plasma APV Parameter: CL/F</title>
          <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. CL/F=apparent plasma clearance.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>milliliters/minute/kilogram</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="7.62" upper_limit="14.5"/>
                    <measurement group_id="O2" value="10.6" lower_limit="6.09" upper_limit="18.5"/>
                    <measurement group_id="O3" value="6.57" lower_limit="2.08" upper_limit="20.7"/>
                    <measurement group_id="O4" value="4.95" lower_limit="0.745" upper_limit="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Steady State Plasma APV Parameter: CL/F</title>
        <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. CL/F=apparent plasma clearance.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Steady State Plasma APV Parameter: CL/F</title>
          <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. CL/F=apparent plasma clearance.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>milliliters/minute</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278" lower_limit="41.2" upper_limit="1882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Steady State Plasma APV Parameter: t1/2</title>
        <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. t1/2=elimination half-life. t1/2=elimination half-life.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Steady State Plasma APV Parameter: t1/2</title>
          <description>Geometric mean is a type of &quot;average&quot; that indicates the central tendency of a set of values and is calculated by multiplying all the numbers in a set, and then taking the nth root of the resulting product. t1/2=elimination half-life. t1/2=elimination half-life.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="11.1" upper_limit="27.7"/>
                    <measurement group_id="O2" value="13.6" lower_limit="9.02" upper_limit="20.4"/>
                    <measurement group_id="O3" value="15.0" lower_limit="7.93" upper_limit="28.2"/>
                    <measurement group_id="O4" value="14.9" lower_limit="4.78" upper_limit="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean of Plasma APV Parameter: AUC0-tau</title>
        <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years vs. Historical Adult Data</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean of Plasma APV Parameter: AUC0-tau</title>
          <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>hours*micrograms/milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.695" lower_limit="0.578" upper_limit="0.835"/>
                    <measurement group_id="O2" value="0.699" lower_limit="0.577" upper_limit="0.848"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.800" upper_limit="1.54"/>
                    <measurement group_id="O4" value="1.06" lower_limit="0.761" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean of Plasma APV Parameter: Cmax</title>
        <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4.</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years vs. Historical Adult Data</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years vs. Historical Adult Data</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean of Plasma APV Parameter: Cmax</title>
          <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>micrograms/milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.663" lower_limit="0.555" upper_limit="0.791"/>
                    <measurement group_id="O2" value="0.676" lower_limit="0.560" upper_limit="0.814"/>
                    <measurement group_id="O3" value="0.917" lower_limit="0.667" upper_limit="1.26"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.747" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean of Plasma APV Parameter: Ctau</title>
        <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
        <time_frame>0, 1, 2, 4, 8, 12, and 24 hours post dosing at Week 4.</time_frame>
        <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 2-5 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 2-5 years</description>
          </group>
          <group group_id="O2">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 6-11 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 6-11 years</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 30/6 mg/kg Once Daily (Suspension), 12-18 Years</title>
            <description>FPV/RTV 30/6 mg/kg once daily (suspension), 12-18 years</description>
          </group>
          <group group_id="O4">
            <title>FPV/RTV 1400/200 mg Once Daily (Tablet), 12-18 Years</title>
            <description>FPV/RTV 1400/200 mg once daily (tablet), 12-18 years</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean of Plasma APV Parameter: Ctau</title>
          <description>A blood sample was drawn on Week 4 over 24 hours (at 0, 1, 2, 4, 8, 12, and 24 hours post dosing). Ratio of geometric least squares mean (90% CI) are presented. Ctau=trough concentration. PK Parameters for QD and BID are compared with Historical adult data. Least squares mean (LSM) are the group means after having controlled for a covariate (i.e., holding it constant at some typical value of the covariate, such as its mean value). LSM is calculated by taking the average of the means within a treatment.</description>
          <population>The PK Parameter Population included all participants who underwent plasma PK sampling and provided full PK profiles with evaluable plasma APV PK parameter data; thus, the sample sizes were limited. Results are stratified by age cohort and formulation since these factors can impact PK profiles.</population>
          <units>microgram per milliliter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.716" lower_limit="0.548" upper_limit="0.936"/>
                    <measurement group_id="O2" value="0.837" lower_limit="0.663" upper_limit="1.06"/>
                    <measurement group_id="O3" value="0.963" lower_limit="0.696" upper_limit="1.33"/>
                    <measurement group_id="O4" value="0.706" lower_limit="0.568" upper_limit="0.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FPV/RTV</title>
          <description>Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Borderline personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Impulse control disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

